查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1780273

思覺失調症治療藥的全球市場，各思覺失調症子類型，各類藥物，各給藥途徑，各流通管道，各地區，機會，預測，2018年～2032年

Global Schizophrenia Drugs Market Assessment, By Schizophrenia Subtype, By Therapeutic Class, By Route of Administration, By Distribution Channel, By Region, Opportunities and Forecast, 2018-2032F
出版日期: | 出版商: Markets & Data | 英文 226 Pages | 商品交期: 3-5個工作天內

價格

全球精神分裂症藥物市場預計將從2024年的90.3億美元增長到2032年的134.7億美元，預測期內（2025-2032年）的複合年增長率為5.13%。市場成長的動力源自於社會經濟、環境和遺傳因素導致世界各地精神分裂症盛行率不斷上升，診斷技術的快速進步以及人們認知度的不斷提高。製藥技術和醫學研究的快速進步顯著改善了精神分裂症的治療，為市場創造了良好的成長機會。

市場成長的動力源自於人們對各種精神疾病認識的不斷提高，以及精神分裂症等疾病日益被非人格化。此外，副作用較少、療效較高的下一代抗精神病藥物的開發，進一步增強了藥物介入在精神分裂症等疾病管理中的作用。此外，精神健康計畫的增加、醫療保險覆蓋範圍的加強以及綜合護理模式的建立，進一步確保了治療依從性和診斷率的提高。

目錄

第1章 計劃的範圍和定義

第2章 調查手法

第3章 美國的關稅的影響

第4章 摘要整理

第5章 全球思覺失調症治療藥市場展望，2018年～2032年

  • 市場規模分析與預測
    • 各金額
  • 市場佔有率分析與預測
    • 思覺失調症的各子類型
      • 偏執型精神分裂症
      • 青春型（混亂型）精神分裂症
      • 緊張型精神分裂症
      • 未分化型精神分裂症
      • 殘留型精神分裂症
    • 各類藥物
      • 第二世代抗精神病藥(非典型)
      • 第三代抗精神病藥
      • 其他的藥物類別
    • 各給藥途徑
      • 口服
      • 非口服(注射)
    • 各流通管道
      • 醫院藥局
      • 線上藥局
      • 零售藥局
    • 各地區
      • 北美
      • 歐洲
      • 亞太地區
      • 南美
      • 中東·非洲
    • 各企業市場佔有率分析(前五名公司以及其他- 各金額，2024年)
  • 2024年市場地圖分析
    • 思覺失調症的各子類型
    • 各類藥物
    • 各給藥途徑
    • 各流通管道
    • 各地區

第6章 北美的思覺失調症治療藥市場展望，2018年～2032年

  • 市場規模分析與預測
    • 各金額
  • 市場佔有率分析與預測
    • 思覺失調症的各子類型
      • 偏執型精神分裂症
      • 青春型（混亂型）精神分裂症
      • 緊張型精神分裂症
      • 未分化型精神分裂症
      • 殘留型精神分裂症
    • 各類藥物
      • 第二世代抗精神病藥(非典型)
      • 第三代抗精神病藥
      • 其他的藥物類別
    • 各給藥途徑
      • 口服
      • 非口服(注射)
    • 各流通管道
      • 醫院藥局
      • 線上藥局
      • 零售藥局
    • 各國佔有率
      • 美國
      • 加拿大
      • 墨西哥
  • 各國市場評估
    • 美國的思覺失調症治療藥市場展望，2018年～2032年
      • 市場規模分析與預測
      • 市場佔有率分析與預測
    • 加拿大
    • 墨西哥

所有部門市場均涵蓋所有地區和國家。

第7章 歐洲的思覺失調症治療藥市場展望，2018年～2032年

  • 德國
  • 法國
  • 義大利
  • 英國
  • 俄羅斯
  • 荷蘭
  • 西班牙
  • 土耳其
  • 波蘭

第8章 亞太地區的思覺失調症治療藥市場展望，2018年～2032年

  • 印度
  • 中國
  • 日本
  • 澳洲
  • 越南
  • 韓國
  • 印尼
  • 菲律賓

第9章 南美的思覺失調症治療藥市場展望，2018年～2032年

  • 巴西
  • 阿根廷

第10章 中東·非洲的思覺失調症治療藥市場展望，2018年～2032年

  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國
  • 南非

第11章 需求供給分析

第12章 價值鏈分析

第13章 波特的五力分析

第14章 大環境分析

第15章 價格分析

第16章 市場動態

  • 推動市場要素
  • 市場課題

第17章 市場趨勢與發展

第18章 法律規範

  • 臨床試驗
  • 法規當局的認證

第19章 專利的形勢

第20章 案例研究

第21章 競爭情形

  • 前五名市場領導公司的競爭矩陣
  • 前五名企業的SWOT分析
  • 前10名市場主要企業的形勢
    • Johnson &Johnson Services, Inc.
      • 公司概要
      • 主要經營團隊
      • 產品和服務
      • 財務狀況(報告那樣)
      • 主要市場的著重和地理存在感
      • 最近的趨勢/合作/夥伴關係/合併和收購
    • Eli Lilly and Company
    • Alkermes, Inc.
    • Otsuka Pharmaceutical Co., Ltd.
    • AbbVie Inc.
    • Bristol-Myers Squibb Company
    • AstraZeneca PLC
    • H. Lundbeck A/S
    • Lupin Limited
    • Vanda Pharmaceuticals Inc.(Vanda)

以上公司非基於市場佔有率排序，並且可能會根據研究過程中可用的信息而變化。

第22章 策略性建議

第23章 關於調查公司·免責聲明

Product Code: MX13819

Global schizophrenia drugs market is projected to witness a CAGR of 5.13% during the forecast period 2025-2032, growing from USD 9.03 billion in 2024 to USD 13.47 billion in 2032. The market's growth is bolstered by the increasing prevalence of schizophrenia in different regions across the globe, owing to socio-economic, environmental, and genetic factors, rapid advancements in diagnostic techniques, and increasing awareness. Rapid advancements in pharmaceutical technology and medical research have significantly improved the treatment landscape for schizophrenia, providing lucrative growth opportunities for the market.

The market's growth is further bolstered by the rising awareness about various mental health disorders and increasing destigmatization of diseases such as schizophrenia. Moreover, the development of next-generation antipsychotic medications, that offer reduced side effects and improved efficacy, are further augmenting the role of pharmaceutical interventions in the management of conditions such as schizophrenia. Moreover, increasing mental health programs, enhanced health coverage, and integrated care models are further ensuring improved treatment adherence and diagnosis rate.

Increasing Cases of Schizophrenia Boosts Market Demand

Rising cases of schizophrenia in different regions across the globe owing to lifestyle changes, environmental stressors, and genetic predispositions is propelling the market's demand. As per the estimates of the Cross River Therapy, approximately 24 million people across the globe have schizophrenia. Increasing urbanization is also a contributor as various studies have linked urbanization with a higher risk of schizophrenia due to environmental pollution, social fragmentation, and stress. Increasing investments from the private sector coupled with supportive government initiatives are improving treatment adherence, access to mental health care, and increasing diagnosis rates. Additionally, the rapid expansion of the aging population is also propelling the market's demand as late-onset cases of schizophrenia among the older population increase. The rising requirement for effective treatment options in combination with early diagnosis, rising research activities, and increasing awareness are propelling the market's expansion, providing lucrative growth opportunities for the market.

Rising Research Activities Support Market Expansion

The schizophrenia drugs market is witnessing increased investment in research and development aimed at creating next-generation therapeutics with novel mechanisms of action. Current antipsychotics largely target dopamine receptors, which, although effective for positive symptoms, do little for negative symptoms like social withdrawal, apathy, or cognitive impairment. Emerging treatments aim to provide more balanced symptom control with fewer extrapyramidal side effects. Additionally, advancements in pharmacogenomics and biomarker research are paving the way for personalized medicine approaches in psychiatry, enabling the identification of patient subgroups who may respond better to specific treatments based on genetic, metabolic, and neurobiological profiles. The pipeline is also rich with reformulated therapies aimed at improving patient compliance, including once a month and once in three months injectables, along with subdermal implants and transdermal patches.

Such efforts are also allowing pharmaceutical companies to gain approvals from different regulatory bodies such as the United States Food and Drug Administration (US FDA), further supporting the market's expansion. For instance, in January 2025, Alembic Pharmaceuticals Limited received approval from the US FDA for Brexpiprazole tablets, indicated for treating schizophrenia in both pediatric and adult patients. Such approvals are incentivizing the leading pharmaceutical companies to invest in research and development activities, further supporting the market's expansion.

Oral Segment Accounts for Significant Share of the Market

The segment's dominance can be attributed to the ease of use associated with oral drugs. They are widely utilized as they do not require medical supervision for administration, supporting better adherence to long-term treatment plans, and allowing for individualized dosing adjustments. Furthermore, oral formulations have a broad range of options available, including both generic and branded version, increasing their affordability and accessibility for a larger patient population. Moreover, leading market players are also focusing on launching new drugs, further supporting the segment's expansion. For instance, in October 2024, Bristol-Myers Squibb Company launched Cobenfy capsules in the United States for treating schizophrenia. Additionally, healthcare providers also favor oral medications for ongoing and initial treatments as they ensure increased patient adherence due to easy administration, further encouraging market players to focus on innovations and new launches, providing lucrative growth opportunities for the market.

North America Holds Major Market Share

The market's growth in North America is supported by the strong presence of leading market players, rising awareness about psychiatric conditions and the different treatment options that are available and increasing investments in research and development activities. The rising cases of schizophrenia in the region are also supporting the market's expansion. As per the estimates of the National Alliance on Mental Illness (NAMI) approximately 0.25% to 0.64% of adults in the United States are living with schizophrenia.

Improved mental health screening and an increasing number of awareness campaigns are allowing more individuals to seek treatment. Additionally, rapid advancements in medical research are ensuring the availability of more effectively targeted therapies, propelling the market's expansion. Additionally, the growing emphasis on community-based treatment programs and outpatient care, that heavily rely on pharmaceutical management, are further propelling the market's demand.

Impact of the U.S. Tariff on Global Schizophrenia Drugs Market

The recently imposed tariffs by the United States are having a significant impact on the market for schizophrenia drugs as they are disrupting supply chains, resulting in increased costs of essential drugs and affecting the accessibility of essential medications. The increased costs and uncertainties posed by the tariffs could discourage pharmaceutical companies from investing in research and development activities, resulting in the availability of fewer treatment options for the patient population in the long run. Moreover, introduction of retaliatory tariffs could further complicate the supply chains for schizophrenia drugs.

Key Players Landscape and Outlook

The key players of the market are engaging in mergers and acquisitions and focusing on launching new products to expand their product portfolios and strengthen their presence in the industry. For instance, in April 2025, Johnson & Johnson Services, Inc. completed the acquisition of Intra-Cellular Therapies, Inc., allowing the former to expand its product offerings for neurodegenerative and neuropsychiatric disorders. Johnson & Johnson's global reach, commercialization expertise, and investment in neuroscience research and development are expected to support wider adoption of CAPLYTA and other schizophrenia drugs provided by Intra-Cellular Therapies, Inc., bolstering the expansion and competitiveness of the schizophrenia drugs market across the globe.

Table of Contents

1. Project Scope and Definitions

2. Research Methodology

3. Impact of the U.S. Tariffs

4. Executive Summary

5. Global Schizophrenia Drugs Market Outlook, 2018-2032F

  • 5.1. Market Size Analysis & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share Analysis & Forecast
    • 5.2.1. By Schizophrenia Subtype
      • 5.2.1.1. Paranoid Schizophrenia
      • 5.2.1.2. Hebephrenic (Disorganized) Schizophrenia
      • 5.2.1.3. Catatonic Schizophrenia
      • 5.2.1.4. Undifferentiated Schizophrenia
      • 5.2.1.5. Residual Schizophrenia
    • 5.2.2. By Therapeutic Class
      • 5.2.2.1. Second-Generation Antipsychotics (Atypical)
      • 5.2.2.2. Third-Generation Antipsychotics
      • 5.2.2.3. Other Therapeutic Classes
    • 5.2.3. Route of Administration
      • 5.2.3.1. Oral
      • 5.2.3.2. Parenteral (Injections)
    • 5.2.4. By Distribution Channel
      • 5.2.4.1. Hospital Pharmacies
      • 5.2.4.2. Online Pharmacies
      • 5.2.4.3. Retail Pharmacies
    • 5.2.5. By Region
      • 5.2.5.1. North America
      • 5.2.5.2. Europe
      • 5.2.5.3. Asia-Pacific
      • 5.2.5.4. South America
      • 5.2.5.5. Middle East and Africa
    • 5.2.6. By Company Market Share Analysis (Top 5 Companies and Others - By Value, 2024)
  • 5.3. Market Map Analysis, 2024
    • 5.3.1. By Schizophrenia Subtype
    • 5.3.2. By Therapeutic Class
    • 5.3.3. By Route of Administration
    • 5.3.4. By Distribution Channel
    • 5.3.5. By Region

6. North America Schizophrenia Drugs Market Outlook, 2018-2032F

  • 6.1. Market Size Analysis & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share Analysis & Forecast
    • 6.2.1. By Schizophrenia Subtype
      • 6.2.1.1. Paranoid Schizophrenia
      • 6.2.1.2. Hebephrenic (Disorganized) Schizophrenia
      • 6.2.1.3. Catatonic Schizophrenia
      • 6.2.1.4. Undifferentiated Schizophrenia
      • 6.2.1.5. Residual Schizophrenia
    • 6.2.2. By Therapeutic Class
      • 6.2.2.1. Second-Generation Antipsychotics (Atypical)
      • 6.2.2.2. Third-Generation Antipsychotics
      • 6.2.2.3. Other Therapeutic Classes
    • 6.2.3. Route of Administration
      • 6.2.3.1. Oral
      • 6.2.3.2. Parenteral (Injections)
    • 6.2.4. By Distribution Channel
      • 6.2.4.1. Hospital Pharmacies
      • 6.2.4.2. Online Pharmacies
      • 6.2.4.3. Retail Pharmacies
    • 6.2.5. By Country Share
      • 6.2.5.1. United States
      • 6.2.5.2. Canada
      • 6.2.5.3. Mexico
  • 6.3. Country Market Assessment
    • 6.3.1. United States Schizophrenia Drugs Market Outlook, 2018-2032F*
      • 6.3.1.1. Market Size Analysis & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share Analysis & Forecast
          • 6.3.1.2.1.1. By Schizophrenia Subtype
          • 6.3.1.2.1.1.1. Paranoid Schizophrenia
          • 6.3.1.2.1.1.2. Hebephrenic (Disorganized) Schizophrenia
          • 6.3.1.2.1.1.3. Catatonic Schizophrenia
          • 6.3.1.2.1.1.4. Undifferentiated Schizophrenia
          • 6.3.1.2.1.1.5. Residual Schizophrenia
          • 6.3.1.2.1.2. By Therapeutic Class
          • 6.3.1.2.1.2.1. Second-Generation Antipsychotics (Atypical)
          • 6.3.1.2.1.2.2. Third-Generation Antipsychotics
          • 6.3.1.2.1.2.3. Other Therapeutic Classes
          • 6.3.1.2.1.3. Route of Administration
          • 6.3.1.2.1.3.1. Oral
          • 6.3.1.2.1.3.2. Parenteral (Injections)
          • 6.3.1.2.1.4. By Distribution Channel
          • 6.3.1.2.1.4.1. Hospital Pharmacies
          • 6.3.1.2.1.4.2. Online Pharmacies
          • 6.3.1.2.1.4.3. Retail Pharmacies
    • 6.3.2. Canada
    • 6.3.3. Mexico

All segments will be provided for all regions and countries covered

7. Europe Schizophrenia Drugs Market Outlook, 2018-2032F

  • 7.1. Germany
  • 7.2. France
  • 7.3. Italy
  • 7.4. United Kingdom
  • 7.5. Russia
  • 7.6. Netherlands
  • 7.7. Spain
  • 7.8. Turkey
  • 7.9. Poland

8. Asia-Pacific Schizophrenia Drugs Market Outlook, 2018-2032F

  • 8.1. India
  • 8.2. China
  • 8.3. Japan
  • 8.4. Australia
  • 8.5. Vietnam
  • 8.6. South Korea
  • 8.7. Indonesia
  • 8.8. Philippines

9. South America Schizophrenia Drugs Market Outlook, 2018-2032F

  • 9.1. Brazil
  • 9.2. Argentina

10. Middle East and Africa Schizophrenia Drugs Market Outlook, 2018-2032F

  • 10.1. Saudi Arabia
  • 10.2. UAE
  • 10.3. South Africa

11. Demand Supply Analysis

12. Value Chain Analysis

13. Porter's Five Forces Analysis

14. PESTLE Analysis

15. Pricing Analysis

16. Market Dynamics

  • 16.1. Market Drivers
  • 16.2. Market Challenges

17. Market Trends and Developments

18. Regulatory Framework

  • 18.1. Clinical Trials
  • 18.2. Regulatory Approvals

19. Patent Landscape

20. Case Studies

21. Competitive Landscape

  • 21.1. Competition Matrix of Top 5 Market Leaders
  • 21.2. SWOT Analysis for Top 5 Players
  • 21.3. Key Players Landscape for Top 10 Market Players
    • 21.3.1. Johnson & Johnson Services, Inc.
      • 21.3.1.1. Company Details
      • 21.3.1.2. Key Management Personnel
      • 21.3.1.3. Products and Services
      • 21.3.1.4. Financials (As Reported)
      • 21.3.1.5. Key Market Focus and Geographical Presence
      • 21.3.1.6. Recent Developments/Collaborations/Partnerships/Mergers and Acquisition
    • 21.3.2. Eli Lilly and Company
    • 21.3.3. Alkermes, Inc.
    • 21.3.4. Otsuka Pharmaceutical Co., Ltd.
    • 21.3.5. AbbVie Inc.
    • 21.3.6. Bristol-Myers Squibb Company
    • 21.3.7. AstraZeneca PLC
    • 21.3.8. H. Lundbeck A/S
    • 21.3.9. Lupin Limited
    • 21.3.10. Vanda Pharmaceuticals Inc. (Vanda)

Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work.

22. Strategic Recommendations

23. About Us and Disclaimer

List of Tables

  • Table 1. Competition Matrix of Top 5 Market Leaders
  • Table 2. Mergers & Acquisitions/ Joint Ventures (If Applicable)
  • Table 3. About Us - Regions and Countries Where We Have Executed Client Projects

List of Figures

  • Figure 1. Global Schizophrenia Drugs Market, By Value, In USD Billion, 2018-2032F
  • Figure 2. Global Schizophrenia Drugs Market Share (%), By Schizophrenia Subtype, 2018-2032F
  • Figure 3. Global Schizophrenia Drugs Market Share (%), By Therapeutic Class, 2018-2032F
  • Figure 4. Global Schizophrenia Drugs Market Share (%), By Route of Administration, 2018-2032F
  • Figure 5. Global Schizophrenia Drugs Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 6. Global Schizophrenia Drugs Market Share (%), By Region, 2018-2032F
  • Figure 7. North America Schizophrenia Drugs Market, By Value, In USD Billion, 2018-2032F
  • Figure 8. North America Schizophrenia Drugs Market Share (%), By Schizophrenia Subtype, 2018-2032F
  • Figure 9. North America Schizophrenia Drugs Market Share (%), By Therapeutic Class, 2018-2032F
  • Figure 10. North America Schizophrenia Drugs Market Share (%), By Route of Administration, 2018-2032F
  • Figure 11. North America Schizophrenia Drugs Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 12. North America Schizophrenia Drugs Market Share (%), By Country, 2018-2032F
  • Figure 13. United States Schizophrenia Drugs Market, By Value, In USD Billion, 2018-2032F
  • Figure 14. United States Schizophrenia Drugs Market Share (%), By Schizophrenia Subtype, 2018-2032F
  • Figure 15. United States Schizophrenia Drugs Market Share (%), By Therapeutic Class, 2018-2032F
  • Figure 16. United States Schizophrenia Drugs Market Share (%), By Route of Administration, 2018-2032F
  • Figure 17. United States Schizophrenia Drugs Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 18. Canada Schizophrenia Drugs Market, By Value, In USD Billion, 2018-2032F
  • Figure 19. Canada Schizophrenia Drugs Market Share (%), By Schizophrenia Subtype, 2018-2032F
  • Figure 20. Canada Schizophrenia Drugs Market Share (%), By Therapeutic Class, 2018-2032F
  • Figure 21. Canada Schizophrenia Drugs Market Share (%), By Route of Administration, 2018-2032F
  • Figure 22. Canada Schizophrenia Drugs Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 23. Mexico Schizophrenia Drugs Market, By Value, In USD Billion, 2018-2032F
  • Figure 24. Mexico Schizophrenia Drugs Market Share (%), By Schizophrenia Subtype, 2018-2032F
  • Figure 25. Mexico Schizophrenia Drugs Market Share (%), By Therapeutic Class, 2018-2032F
  • Figure 26. Mexico Schizophrenia Drugs Market Share (%), By Route of Administration, 2018-2032F
  • Figure 27. Mexico Schizophrenia Drugs Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 28. Europe Schizophrenia Drugs Market, By Value, In USD Billion, 2018-2032F
  • Figure 29. Europe Schizophrenia Drugs Market Share (%), By Schizophrenia Subtype, 2018-2032F
  • Figure 30. Europe Schizophrenia Drugs Market Share (%), By Therapeutic Class, 2018-2032F
  • Figure 31. Europe Schizophrenia Drugs Market Share (%), By Route of Administration, 2018-2032F
  • Figure 32. Europe Schizophrenia Drugs Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 33. Europe Schizophrenia Drugs Market Share (%), By Country, 2018-2032F
  • Figure 34. Germany Schizophrenia Drugs Market, By Value, In USD Billion, 2018-2032F
  • Figure 35. Germany Schizophrenia Drugs Market Share (%), By Schizophrenia Subtype, 2018-2032F
  • Figure 36. Germany Schizophrenia Drugs Market Share (%), By Therapeutic Class, 2018-2032F
  • Figure 37. Germany Schizophrenia Drugs Market Share (%), By Route of Administration, 2018-2032F
  • Figure 38. Germany Schizophrenia Drugs Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 39. France Schizophrenia Drugs Market, By Value, In USD Billion, 2018-2032F
  • Figure 40. France Schizophrenia Drugs Market Share (%), By Schizophrenia Subtype, 2018-2032F
  • Figure 41. France Schizophrenia Drugs Market Share (%), By Therapeutic Class, 2018-2032F
  • Figure 42. France Schizophrenia Drugs Market Share (%), By Route of Administration, 2018-2032F
  • Figure 43. France Schizophrenia Drugs Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 44. Italy Schizophrenia Drugs Market, By Value, In USD Billion, 2018-2032F
  • Figure 45. Italy Schizophrenia Drugs Market Share (%), By Schizophrenia Subtype, 2018-2032F
  • Figure 46. Italy Schizophrenia Drugs Market Share (%), By Therapeutic Class, 2018-2032F
  • Figure 47. Italy Schizophrenia Drugs Market Share (%), By Route of Administration, 2018-2032F
  • Figure 48. Italy Schizophrenia Drugs Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 49. United Kingdom Schizophrenia Drugs Market, By Value, In USD Billion, 2018-2032F
  • Figure 50. United Kingdom Schizophrenia Drugs Market Share (%), By Schizophrenia Subtype, 2018-2032F
  • Figure 51. United Kingdom Schizophrenia Drugs Market Share (%), By Therapeutic Class, 2018-2032F
  • Figure 52. United Kingdom Schizophrenia Drugs Market Share (%), By Route of Administration, 2018-2032F
  • Figure 53. United Kingdom Schizophrenia Drugs Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 54. Russia Schizophrenia Drugs Market, By Value, In USD Billion, 2018-2032F
  • Figure 55. Russia Schizophrenia Drugs Market Share (%), By Schizophrenia Subtype, 2018-2032F
  • Figure 56. Russia Schizophrenia Drugs Market Share (%), By Therapeutic Class, 2018-2032F
  • Figure 57. Russia Schizophrenia Drugs Market Share (%), By Route of Administration, 2018-2032F
  • Figure 58. Russia Schizophrenia Drugs Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 59. Netherlands Schizophrenia Drugs Market, By Value, In USD Billion, 2018-2032F
  • Figure 60. Netherlands Schizophrenia Drugs Market Share (%), By Schizophrenia Subtype, 2018-2032F
  • Figure 61. Netherlands Schizophrenia Drugs Market Share (%), By Therapeutic Class, 2018-2032F
  • Figure 62. Netherlands Schizophrenia Drugs Market Share (%), By Route of Administration, 2018-2032F
  • Figure 63. Netherlands Schizophrenia Drugs Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 64. Spain Schizophrenia Drugs Market, By Value, In USD Billion, 2018-2032F
  • Figure 65. Spain Schizophrenia Drugs Market Share (%), By Schizophrenia Subtype, 2018-2032F
  • Figure 66. Spain Schizophrenia Drugs Market Share (%), By Therapeutic Class, 2018-2032F
  • Figure 67. Spain Schizophrenia Drugs Market Share (%), By Route of Administration, 2018-2032F
  • Figure 68. Spain Schizophrenia Drugs Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 69. Turkey Schizophrenia Drugs Market, By Value, In USD Billion, 2018-2032F
  • Figure 70. Turkey Schizophrenia Drugs Market Share (%), By Schizophrenia Subtype, 2018-2032F
  • Figure 71. Turkey Schizophrenia Drugs Market Share (%), By Therapeutic Class, 2018-2032F
  • Figure 72. Turkey Schizophrenia Drugs Market Share (%), By Route of Administration, 2018-2032F
  • Figure 73. Turkey Schizophrenia Drugs Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 74. Poland Schizophrenia Drugs Market, By Value, In USD Billion, 2018-2032F
  • Figure 75. Poland Schizophrenia Drugs Market Share (%), By Schizophrenia Subtype, 2018-2032F
  • Figure 76. Poland Schizophrenia Drugs Market Share (%), By Therapeutic Class, 2018-2032F
  • Figure 77. Poland Schizophrenia Drugs Market Share (%), By Route of Administration, 2018-2032F
  • Figure 78. Poland Schizophrenia Drugs Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 79. Asia-Pacific Schizophrenia Drugs Market, By Value, In USD Billion, 2018-2032F
  • Figure 80. Asia-Pacific Schizophrenia Drugs Market Share (%), By Schizophrenia Subtype, 2018-2032F
  • Figure 81. Asia-Pacific Schizophrenia Drugs Market Share (%), By Therapeutic Class, 2018-2032F
  • Figure 82. Asia-Pacific Schizophrenia Drugs Market Share (%), By Route of Administration, 2018-2032F
  • Figure 83. Asia-Pacific Schizophrenia Drugs Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 84. Asia-Pacific Schizophrenia Drugs Market Share (%), By Country, 2018-2032F
  • Figure 85. India Schizophrenia Drugs Market, By Value, In USD Billion, 2018-2032F
  • Figure 86. India Schizophrenia Drugs Market Share (%), By Schizophrenia Subtype, 2018-2032F
  • Figure 87. India Schizophrenia Drugs Market Share (%), By Therapeutic Class, 2018-2032F
  • Figure 88. India Schizophrenia Drugs Market Share (%), By Route of Administration, 2018-2032F
  • Figure 89. India Schizophrenia Drugs Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 90. China Schizophrenia Drugs Market, By Value, In USD Billion, 2018-2032F
  • Figure 91. China Schizophrenia Drugs Market Share (%), By Schizophrenia Subtype, 2018-2032F
  • Figure 92. China Schizophrenia Drugs Market Share (%), By Therapeutic Class, 2018-2032F
  • Figure 93. China Schizophrenia Drugs Market Share (%), By Route of Administration, 2018-2032F
  • Figure 94. China Schizophrenia Drugs Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 95. Japan Schizophrenia Drugs Market, By Value, In USD Billion, 2018-2032F
  • Figure 96. Japan Schizophrenia Drugs Market Share (%), By Schizophrenia Subtype, 2018-2032F
  • Figure 97. Japan Schizophrenia Drugs Market Share (%), By Therapeutic Class, 2018-2032F
  • Figure 98. Japan Schizophrenia Drugs Market Share (%), By Route of Administration, 2018-2032F
  • Figure 99. Japan Schizophrenia Drugs Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 100. Australia Schizophrenia Drugs Market, By Value, In USD Billion, 2018-2032F
  • Figure 101. Australia Schizophrenia Drugs Market Share (%), By Schizophrenia Subtype, 2018-2032F
  • Figure 102. Australia Schizophrenia Drugs Market Share (%), By Therapeutic Class, 2018-2032F
  • Figure 103. Australia Schizophrenia Drugs Market Share (%), By Route of Administration, 2018-2032F
  • Figure 104. Australia Schizophrenia Drugs Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 105. Vietnam Schizophrenia Drugs Market, By Value, In USD Billion, 2018-2032F
  • Figure 106. Vietnam Schizophrenia Drugs Market Share (%), By Schizophrenia Subtype, 2018-2032F
  • Figure 107. Vietnam Schizophrenia Drugs Market Share (%), By Therapeutic Class, 2018-2032F
  • Figure 108. Vietnam Schizophrenia Drugs Market Share (%), By Route of Administration, 2018-2032F
  • Figure 109. Vietnam Schizophrenia Drugs Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 110. South Korea Schizophrenia Drugs Market, By Value, In USD Billion, 2018-2032F
  • Figure 111. South Korea Schizophrenia Drugs Market Share (%), By Schizophrenia Subtype, 2018-2032F
  • Figure 112. South Korea Schizophrenia Drugs Market Share (%), By Therapeutic Class, 2018-2032F
  • Figure 113. South Korea Schizophrenia Drugs Market Share (%), By Route of Administration, 2018-2032F
  • Figure 114. South Korea Schizophrenia Drugs Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 115. Indonesia Schizophrenia Drugs Market, By Value, In USD Billion, 2018-2032F
  • Figure 116. Indonesia Schizophrenia Drugs Market Share (%), By Schizophrenia Subtype, 2018-2032F
  • Figure 117. Indonesia Schizophrenia Drugs Market Share (%), By Therapeutic Class, 2018-2032F
  • Figure 118. Indonesia Schizophrenia Drugs Market Share (%), By Route of Administration, 2018-2032F
  • Figure 119. Indonesia Schizophrenia Drugs Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 120. Philippines Schizophrenia Drugs Market, By Value, In USD Billion, 2018-2032F
  • Figure 121. Philippines Schizophrenia Drugs Market Share (%), By Schizophrenia Subtype, 2018-2032F
  • Figure 122. Philippines Schizophrenia Drugs Market Share (%), By Therapeutic Class, 2018-2032F
  • Figure 123. Philippines Schizophrenia Drugs Market Share (%), By Route of Administration, 2018-2032F
  • Figure 124. Philippines Schizophrenia Drugs Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 125. South America Schizophrenia Drugs Market, By Value, In USD Billion, 2018-2032F
  • Figure 126. South America Schizophrenia Drugs Market Share (%), By Schizophrenia Subtype, 2018-2032F
  • Figure 127. South America Schizophrenia Drugs Market Share (%), By Therapeutic Class, 2018-2032F
  • Figure 128. South America Schizophrenia Drugs Market Share (%), By Route of Administration, 2018-2032F
  • Figure 129. South America Schizophrenia Drugs Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 130. South America Schizophrenia Drugs Market Share (%), By Country, 2018-2032F
  • Figure 131. Brazil Schizophrenia Drugs Market, By Value, In USD Billion, 2018-2032F
  • Figure 132. Brazil Schizophrenia Drugs Market Share (%), By Schizophrenia Subtype, 2018-2032F
  • Figure 133. Brazil Schizophrenia Drugs Market Share (%), By Therapeutic Class, 2018-2032F
  • Figure 134. Brazil Schizophrenia Drugs Market Share (%), By Route of Administration, 2018-2032F
  • Figure 135. Brazil Schizophrenia Drugs Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 136. Argentina Schizophrenia Drugs Market, By Value, In USD Billion, 2018-2032F
  • Figure 137. Argentina Schizophrenia Drugs Market Share (%), By Schizophrenia Subtype, 2018-2032F
  • Figure 138. Argentina Schizophrenia Drugs Market Share (%), By Therapeutic Class, 2018-2032F
  • Figure 139. Argentina Schizophrenia Drugs Market Share (%), By Route of Administration, 2018-2032F
  • Figure 140. Argentina Schizophrenia Drugs Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 141. Middle East & Africa Schizophrenia Drugs Market, By Value, In USD Billion, 2018-2032F
  • Figure 142. Middle East & Africa Schizophrenia Drugs Market Share (%), By Schizophrenia Subtype, 2018-2032F
  • Figure 143. Middle East & Africa Schizophrenia Drugs Market Share (%), By Therapeutic Class, 2018-2032F
  • Figure 144. Middle East & Africa Schizophrenia Drugs Market Share (%), By Route of Administration, 2018-2032F
  • Figure 145. Middle East & Africa Schizophrenia Drugs Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 146. Middle East & Africa Schizophrenia Drugs Market Share (%), By Country, 2018-2032F
  • Figure 147. Saudi Arabia Schizophrenia Drugs Market, By Value, In USD Billion, 2018-2032F
  • Figure 148. Saudi Arabia Schizophrenia Drugs Market Share (%), By Schizophrenia Subtype, 2018-2032F
  • Figure 149. Saudi Arabia Schizophrenia Drugs Market Share (%), By Therapeutic Class, 2018-2032F
  • Figure 150. Saudi Arabia Schizophrenia Drugs Market Share (%), By Route of Administration, 2018-2032F
  • Figure 151. Saudi Arabia Schizophrenia Drugs Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 152. UAE Schizophrenia Drugs Market, By Value, In USD Billion, 2018-2032F
  • Figure 153. UAE Schizophrenia Drugs Market Share (%), By Schizophrenia Subtype, 2018-2032F
  • Figure 154. UAE Schizophrenia Drugs Market Share (%), By Therapeutic Class, 2018-2032F
  • Figure 155. UAE Schizophrenia Drugs Market Share (%), By Route of Administration, 2018-2032F
  • Figure 156. UAE Schizophrenia Drugs Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 157. South Africa Schizophrenia Drugs Market, By Value, In USD Billion, 2018-2032F
  • Figure 158. South Africa Schizophrenia Drugs Market Share (%), By Schizophrenia Subtype, 2018-2032F
  • Figure 159. South Africa Schizophrenia Drugs Market Share (%), By Therapeutic Class, 2018-2032F
  • Figure 160. South Africa Schizophrenia Drugs Market Share (%), By Route of Administration, 2018-2032F
  • Figure 161. South Africa Schizophrenia Drugs Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 162. By Schizophrenia Subtype Map-Market Size (USD Billion) & Growth Rate (%), 2024
  • Figure 163. By Therapeutic Class Map-Market Size (USD Billion) & Growth Rate (%), 2024
  • Figure 164. By Route of Administration Map-Market Size (USD Billion) & Growth Rate (%), 2024
  • Figure 165. By Distribution Channel Map-Market Size (USD Billion) & Growth Rate (%), 2024
  • Figure 166. By Region Map-Market Size (USD Billion) & Growth Rate (%), 2024